COVID-19 infection in Crohn's disease under treatment with adalimumab

被引：41
作者：
Tursi, Antonio [1 ]
Angarano, Gioacchino [2 ]
Monno, Laura [2 ]
Saracino, Annalisa [2 ]
Signorile, Fabio [2 ]
Ricciardi, Aurelia [2 ]
Papa, Alfredo [3 ]
机构：
[1] Azienda Sanit Locale Barletta Andria Trani, Gastroenterol Serv, Andria, Puglia, Italy
[2] Univ Bari, Bari Univ Hosp, Div Infect Dis, Bari, Puglia, Italy
[3] Univ Cattolica Sacro Cuore, Fac Med & Surg, Div Internal Med & Gastroenterol, Complesso Integrato Columbus, Rome, Lazio, Italy
来源：
GUT | 2020年 / 69卷 / 07期
关键词：
crohn's disease; immune response;
D O I：
10.1136/gutjnl-2020-321240
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1364 / +
页数：2
相关论文
共 50 条
  • [41] Effectiveness of infliximab after adalimumab failure in Crohn's disease
    Chaparro, Maria
    Andreu, Montserrat
    Barreiro-de Acosta, Manuel
    Garcia-Planella, Esther
    Ricart, Elena
    Domenech, Eugeni
    Esteve, Maria
    Merino, Olga
    Nos, Pilar
    Penalva, Mireia
    Gisbert, Javier P.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (37) : 5219 - 5224
  • [42] Efficacy of adalimumab for Crohn's disease in real clinical practice
    Knyazev, O. V.
    Kagramanova, A. V.
    Ruchkina, I. N.
    Fadeeva, N. A.
    Lishchinskaya, A. A.
    Boldyreva, O. N.
    Zhulina, E. Yu.
    Shcherbakov, P. L.
    Orlova, N. V.
    Kirova, M. V.
    Parfenov, A. I.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (02) : 20 - 27
  • [43] Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
    Panaccione, Remo
    Loftus, Edward V., Jr.
    Binion, David
    McHugh, Kevin
    Alam, Shamsul
    Chen, Naijun
    Guerette, Benoit
    Mulani, Parvez
    Chao, Jingdong
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 2011, 25 (08): : 419 - 425
  • [44] Delayed Infliximab Treatment Affects the Outcomes of Patients With Crohn's Disease During the COVID-19 Epidemic in China: A Propensity Score-Matched Analysis
    Li, Yong
    Chen, Lulu
    Chen, Shuijiao
    Liu, Xiaowei
    FRONTIERS IN MEDICINE, 2022, 8
  • [45] Unilateral Episcleritis Following COVID-19 Booster Vaccination of a Crohn's Disease Patient: A Case Report and Review of the Literature
    Veenis, Aaron
    Haghnegahdar, Megan
    Ajlan, Radwan
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2023, 16 : 91 - 96
  • [46] Adalimumab induced psoriasis in Crohn's disease and treatment with ustekinumab: case report and special histopathological findings
    Qiu, Fang
    Chen, Weiquan
    Zhou, Ying
    FRONTIERS IN MEDICINE, 2025, 11
  • [47] Treatment persistence among bio-naive patients with Crohn's disease initiated on ustekinumab or adalimumab
    Zhdanava, Maryia
    Ding, Zhijie
    Manceur, Ameur M.
    Muser, Erik
    Lefebvre, Patrick
    Holiday, Christopher
    Lafeuille, Marie-Helene
    Pilon, Dominic
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (04) : 533 - 543
  • [48] Periappendicitis during adalimumab treatment for ileocecal Crohn’s disease in a 29-year-old male
    Mizuno S.
    Nakazawa A.
    Ogawa A.
    Hisamatsu T.
    Hirose S.
    Tsukada N.
    Clinical Journal of Gastroenterology, 2015, 8 (3) : 134 - 137
  • [49] Severe cardiomyopathy following treatment with the tumour necrosis factor-α inhibitor adalimumab for Crohn's disease
    Emmert, Maximilian Y.
    Salzberg, Sacha P.
    Emmert, Lorenz S.
    Behjati, Sohil
    Plass, Andre
    Felix, Christian
    Falk, Volkmar
    Gruenenfelder, Juerg
    EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (11) : 1106 - 1109
  • [50] Multiple Sclerosis- Like Demyelinating Lesions During Adalimumab Treatment in a Case with Crohn's Disease
    Sokmen, Okan
    Gocmen, Rahsan
    Tuncer, Asli
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2022, 59 (04): : 342 - 344
12345